Compare CCNE & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCNE | SVRA |
|---|---|---|
| Founded | 1865 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 1995 | 2009 |
| Metric | CCNE | SVRA |
|---|---|---|
| Price | $34.02 | $5.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $34.50 | $7.33 |
| AVG Volume (30 Days) | 109.6K | ★ 1.3M |
| Earning Date | 04-20-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.51% | N/A |
| EPS Growth | ★ 4.18 | N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.21 | N/A |
| Revenue Next Year | $7.00 | $430.87 |
| P/E Ratio | $19.06 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.90 | $3.34 |
| 52 Week High | $36.17 | $7.01 |
| Indicator | CCNE | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 44.69 | 48.32 |
| Support Level | $32.89 | $5.16 |
| Resistance Level | $35.17 | $5.48 |
| Average True Range (ATR) | 0.68 | 0.20 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 34.18 | 49.52 |
CNB Financial Corp is a Pennsylvania-chartered bank. The bank is a full-service bank engaging in a full range of banking activities and services for individual, business, governmental and institutional customers. These activities and services principally include checking, savings, and time deposit accounts; real estate, commercial, industrial, residential and consumer loans; and a variety of other specialized financial services. Its Private Client Solutions division offers a full range of client services, including private banking and wealth and asset management. The banking segment derives its revenue through the operations as a full-service bank services, including trust and wealth management services, for individual, business, governmental, and institutional customers.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).